Biaxin News
Advanced Life pneumonia drug meets all goals in late-stage trial - Reuters
Cethromycin, which is an oral antibiotic treating mild-to-moderate community acquired pneumonia (CAP), cured 94 percent of patients, compared to Biaxin, ...
Cethromycin Achieves All Endpoints in Second Pivotal Phase III ... - PR Newswire (press release)
Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of Care Treatment ...
Advanced Life Sciences lines up share buy deal - Chicago Sun-Times
Advanced Life Sciences last month announced that its next generation antibiotic cethromycin performed as well as Abbott Laboratories’ Biaxin in a late-stage ...
Advanced Life Sciences lines up share buy deal - Chicago Sun-Times
Advanced Life Sciences last month announced that its next generation antibiotic cethromycin performed as well as Abbott Laboratories’ Biaxin in a late-stage ...
Advanced Life Sciences' pneumonia drug tests well against rival ... - Chicago Sun-Times
Both cethromycin and Biaxin are used to treat pneumonia contracted outside of a hospital. The new cethromycin would be the company's first product. ...
Area firm's pneumonia treatment passes test - Chicago Tribune
In trials with patients who had acquired pneumonia in their communities, ALS' cethromycin cured 94 percent, a performance similar to that of Biaxin, ...
UPDATE 1-Advanced Life says pneumonia drug meets goals - Reuters
N: Quote, Profile, Research) Biaxin, a current standard of treatment for CAP that cured 93.8 percent of studied patients, the company said in a statement. ...
Advanced Life Sciences Cites Study Data - Houston Chronicle
In a previous Phase III clinical trial, the antibiotic met its goal of being as effective as Abbott Laboratories' Biaxin. In the most recent study, ...
Advanced Life Sciences' new drug revives stock - Chicago Sun-Times
Advanced Life Sciences said cethromycin cured 94 percent of patients with community acquired pneumonia, compared to Biaxin, the current standard of ...
American Superconductor Provides Initial FY08 Revenue View; To ... - RTT News
The company noted that the study results showed that cethromycin cured 94% of patients with CAP, compared to current standard Biaxin, which cured 93.8% of ...
Biaxin RSS Feed